Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00310895 · ClinicalTrials.gov registry record · Phase 1
Safety and Dose Study of GRN163L Administered to Patients With Refractory or Relapsed Solid Tumor Malignancies
A Phase 1 study, sponsored by Geron Corporation.
- Completed
- Registry status
- Phase 1
- Development phase
- 85
- Enrollment target
NCT00310895: Completed Phase 1 study, sponsored by Geron Corporation.
NCT00310895 is a Phase 1 study that has completed, run by Geron Corporation. The registered enrollment target is 85 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (42% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00310895, a Phase 1 study, has completed, sponsored by Geron Corporation.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 85 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the safety and the maximum tolerated dose of GRN163L administration in treating patients with refractory or relapsed solid tumor malignancies.
Interventions
- DRUG Imetelstat Sodium (GRN163L)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 85 participants |
| Start Date | 2006-03 |
| Est. Completion | 2013-03 |
| Phase | Phase 1 |
What the finished NCT00310895 record still lists
NCT00310895 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 85 participants, a relatively small participant target, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (42% higher).
The record links to 0 conditions, and to 1 intervention - of which Imetelstat Sodium (GRN163L) is the first listed.
NCT00310895 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00310895 about?
NCT00310895 is a clinical study titled "Safety and Dose Study of GRN163L Administered to Patients With Refractory or Relapsed Solid Tumor Malignancies". The purpose of this study is to determine the safety and the maximum tolerated dose of GRN163L administration in treating patients with refractory or relapsed solid tumor malignancies.
What is the current status of trial NCT00310895?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 85 participants. The study started on 2006-03. Estimated completion is 2013-03.
What interventions are being tested in trial NCT00310895?
The interventions under investigation include: Imetelstat Sodium (GRN163L) (DRUG).
Who is sponsoring clinical trial NCT00310895?
This trial is sponsored by Geron Corporation, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00310895's enrollment target sits among peer trials
85 656th of 2000 higher than 1,342 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00842283 · 85 participants
Role of Angiogenesis in Dermatologic Diseases: A Potential Therapeutic Target
- NCT02133196 · 85 participants · Phase 2
T Cell Receptor Immunotherapy for Patients With Metastatic Non-Small Cell Lung Cancer
- NCT03823144 · 85 participants · NA
Intravital Microscopy in Human Solid Tumors
- NCT03875638 · 85 participants · Phase 2
Treating Hyperexcitability in AD With Levetiracetam
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia